Pred-462 [hot] Jun 2026

PRED‑462’s potential (if it indeed hits both ER and PI3K pathways) would differentiate it from existing monotherapies, offering a “one‑pill” solution to circumvent resistance mechanisms that arise from pathway cross‑talk.

| Competitor | Mechanism | Stage | |------------|-----------|-------| | | SERM (ER antagonist in breast tissue) | Approved (1970s) | | Alpelisib | PI3Kα inhibitor | FDA‑approved (2019) | | Ribociclib | CDK4/6 inhibitor | FDA‑approved (2017) | | Emerging SERM‑PI3K hybrid | Dual ER/PI3K blockade (e.g., “AB‑123”) | Phase I/II | PRED-462